1. Home
  2. TWFG vs ALLO Comparison

TWFG vs ALLO Comparison

Compare TWFG & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWFG
  • ALLO
  • Stock Information
  • Founded
  • TWFG 2001
  • ALLO 2017
  • Country
  • TWFG United States
  • ALLO United States
  • Employees
  • TWFG N/A
  • ALLO N/A
  • Industry
  • TWFG
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TWFG
  • ALLO Health Care
  • Exchange
  • TWFG NYSE
  • ALLO Nasdaq
  • Market Cap
  • TWFG 450.0M
  • ALLO 427.7M
  • IPO Year
  • TWFG 2024
  • ALLO 2018
  • Fundamental
  • Price
  • TWFG $29.20
  • ALLO $2.17
  • Analyst Decision
  • TWFG Buy
  • ALLO Strong Buy
  • Analyst Count
  • TWFG 8
  • ALLO 10
  • Target Price
  • TWFG $31.86
  • ALLO $10.06
  • AVG Volume (30 Days)
  • TWFG 71.4K
  • ALLO 9.8M
  • Earning Date
  • TWFG 03-04-2025
  • ALLO 03-13-2025
  • Dividend Yield
  • TWFG N/A
  • ALLO N/A
  • EPS Growth
  • TWFG N/A
  • ALLO N/A
  • EPS
  • TWFG 0.43
  • ALLO N/A
  • Revenue
  • TWFG $194,211,000.00
  • ALLO $43,000.00
  • Revenue This Year
  • TWFG $19.28
  • ALLO N/A
  • Revenue Next Year
  • TWFG $19.60
  • ALLO N/A
  • P/E Ratio
  • TWFG $67.91
  • ALLO N/A
  • Revenue Growth
  • TWFG 26.18
  • ALLO 26.47
  • 52 Week Low
  • TWFG $21.31
  • ALLO $1.32
  • 52 Week High
  • TWFG $36.50
  • ALLO $5.78
  • Technical
  • Relative Strength Index (RSI)
  • TWFG N/A
  • ALLO 55.14
  • Support Level
  • TWFG N/A
  • ALLO $1.32
  • Resistance Level
  • TWFG N/A
  • ALLO $3.78
  • Average True Range (ATR)
  • TWFG 0.00
  • ALLO 0.36
  • MACD
  • TWFG 0.00
  • ALLO 0.10
  • Stochastic Oscillator
  • TWFG 0.00
  • ALLO 34.55

About TWFG TWFG INC

TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: